Brought to you by 
Allergan, Rugen collaborate on OCD, autism treatments
01 Jun 2021
Executive Summary
Allergan PLC and Rugen Therapeutics will together collaborate on the development of new treatments for autism spectrum disorders (ASD) and obsessive-compulsive disorders (OCD).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Allergan, Rugen collaborate on OCD, autism treatments
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice